-
Citi Projects 16% Upside For Becton Dickinson In Upgrade
Tuesday, April 10, 2018 - 2:14pm | 325Read More...Medical supplier Becton Dickinson and Co (NYSE: BDX) is likely to outperform its own expectations, as well as the Street's, according to Citi. The Analyst Analyst Amit Hazan upgraded Becton Dickinson from Neutral to Buy and increased the price target from $237 to $251, suggesting 16-percent...
-
Citi Downgrades Becton Dickinson To Sell
Friday, September 23, 2016 - 8:22am | 303Read More...Citi cut Becton Dickinson and Co (NYSE: BDX) to Sell from Neutral as it expects a cyclical U.S. slowdown to drive lower-than-expected organic growth and impact the stock's recently improved valuation versus peers. The brokerage said it would be tough for the developed markets to sustain its...
-
Following Intuitive Surgical's Solid Q2, Citi Asks What's Next
Wednesday, July 20, 2016 - 4:04pm | 531Read More...Despite solid results from Intuitive Surgical, Inc. (NASDAQ: ISRG), Citi is focusing on "two items that did not absolutely shine" over the most recent quarter. The first of which is systems. Citi said the 130 systems sold grew 10 percent and met Street estimates, but, similar to most quarters in...
-
Edwards Lifesciences Faces 'Sell Event,' Citi Warns
Friday, February 26, 2016 - 11:12am | 253Read More...Citi's Amit Hazan maintained a Sell rating on Edwards Lifesciences Corp (NYSE: EW), with a price target of $67. "The practical benefits of 'superiority' for Sapien 3 TAVR results at ACC late next month are being mostly over exaggerated by Street, in our view, with very high expectations for such an...
-
UPDATE: SunTrust Robinson Humphrey Reiterates on Hologic as Deterioration Story Gains Momentum
Tuesday, November 12, 2013 - 10:41am | 118Read More...In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan reiterated a Reduce rating on Hologic (NASDAQ: HOLX), but lowered the price target from $17.00 to $15.00. In the report, SunTrust Robinson Humphrey noted, “New guidance for FY14 reflects the reality of deteriorating end...
-
UPDATE: SunTrust Initiates Coverage on Myriad Genetics on Pricing Risk
Friday, October 11, 2013 - 10:25am | 138Read More...In a report published Friday, SunTrust Robinson Humphrey analyst Amit Hazan initiated coverage on Myriad Genetics (NASDAQ: MYGN) with a Reduce rating and $17.00 price target. In the report, SunTrust Robinson Humphrey noted, “Our due diligence leads us to believe that the most imminent threat from...
-
UPDATE: SunTrust Maintains Buy on Intuitive Surgical, Positive Outlook
Wednesday, June 5, 2013 - 9:09am | 74Read More...In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan maintained a Buy rating on Intuitive Surgical (NASDAQ: ISRG) maintains its price target of $647.00 In the report, SunTrust cited that, “Three updates are slightly net positive: (1) shipment of monopolar scissors has...
